Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Depemokimab via SSD vs Autoinjector in Healthy Participants
NCT05602025Phase 1Completed
- Sponsor
- GSK
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of depemokimab in asthma (2 arms), sponsored by GSK. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity. Started Dec 2022; status: completed.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05602025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602025.